Silence Therapeutics plc (SLNCF)
OTCMKTS
· Delayed Price · Currency is USD
2.360
0.00 (0.00%)
Apr 27, 2026, 4:00 PM EST
Silence Therapeutics Employees
Silence Therapeutics had 88 employees as of December 31, 2025. The number of employees decreased by 28 or -24.14% compared to the previous year.
Employees
88
Change (1Y)
-28
Growth (1Y)
-24.14%
Revenue / Employee
$6,352
Profits / Employee
-$1,006,955
Market Cap
369.37M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Vaxart | 65 |
| Nuo Therapeutics | 10 |
| Cell Source | 1 |
| Vicapsys Life Sciences | 2 |
| Harvard Apparatus Regenerative Technology | 8 |
Silence Therapeutics News
- 7 weeks ago - Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 4 months ago - Silence Therapeutics Announces Leadership Changes - Business Wire
- 5 months ago - Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference - Business Wire
- 6 months ago - Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 6 months ago - Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) - Business Wire
- 8 months ago - Silence Therapeutics to Participate in September Investor Conferences - Business Wire
- 9 months ago - Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 11 months ago - Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera - Business Wire